CARTITUDE-1 Baseline Demographics
Panelists discuss how the baseline characteristics of CARTITUDE-1 participants underscore the trial’s focus on patients with heavily pretreated and refractory disease.
Baseline characteristics from CARTITUDE-1 reflect a high-risk, refractory population. Approximately 15% had extramedullary disease and 25% had high-risk cytogenetics. The median prior lines of therapy was 6, with nearly all patients refractory to their last regimen.
This highlights the aggressive disease biology and treatment resistance among participants. The trial aimed to assess whether ciltacabtagene autoleucel could provide durable responses despite this challenging clinical profile.
Such a population represents a critical test for the potential of chimeric antigen receptor T-cell therapy to deliver not only responses but also meaningful and lasting remissions in a group with otherwise poor prognosis and few remaining options.
